Killer50 Profiles

  • Adrestia Therapeutics

    Adrestia Therapeutics secured undisclosed Series A  investment from GSK in 2020 to progress technology designed to restore diseased cells by... Read More

  • Quantinuum

    The world’s largest integrated quantum computing company – Quantinuum – was recently rolled out by Honeywell Quantum Solutions and Cambridge Quantum... Read More

  • Qureight

    Qureight is a Cambridge company which uses cloud-based technology to assist in the structuring of image and paired clinical metadata in complex... Read More

  • Porotech

    Porotech is a spin-out from the Cambridge Centre for Gallium Nitride in the Department of Materials Science and Metallurgy at the University of... Read More

  • Nu Quantum

    Nu Quantum is creating high-performance, single-photon technologies that will predicate the future of quantum information processing. The scalable... Read More

  • IQGeo

    IQGeo delivers award-winning geospatial software solutions to telecoms and utility network operators from large multinationals to small regional... Read More

  • Eliem Therapeutics

    Eliem Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address... Read More

  • Cambridge GaN Devices

    Cambridge GaN Devices (CGD) was created to explore and develop a number of unique opportunities in power electronics made possible by the team’s... Read More

  • Apollo Therapeutics

    In 2021, portfolio-based biopharma venture Apollo Therapeutics announced it was  expanding its Cambridge UK and Boston US operations after... Read More

  • PetMedix

    Dr Tom Weaver PetMedix

    PetMedix is applying 30 years of antibody research and the scientific work of two of its founders, Professor Allan Bradley and Dr Jolyon Martin, to... Read More


    SATAVIA has developed a patented software platform to make aviation smarter, and enablie customers to increase cost base efficiency and drive up... Read More

  • Alchemab Therapeutics

    Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of... Read More

  • Sosei Heptares

    Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary... Read More

  • Mogrify

    Mogrify Cambridge

    Mogrify launched in February 2019 with $3.7m seed funding from Ahren Innovation Capital, 24Haymarket and CEO Darrin Disley and went on to secure... Read More

  • Microbiotica

    Dr Mike Romanos

    Microbiotica was only founded in 2016 but is already collaring a European lead in microbiome technology.  It is researching the body’s... Read More

  • Artios Pharma

    Niall Martin of Artios Pharma

    Artios Pharma, a leading DNA Damage Response company developing innovative treatments for cancer, completed an $84 million Series B financing in... Read More

  • PhoreMost

    PhoreMost has grown from a Cambridge University spin-out in 2015 with early proof-of-concept data, to a technically and commercially validated... Read More

  • Astex Pharmaceuticals

    A global biotech company focused on the discovery and development of drugs in oncology and other areas.  Astex Pharmaceuticals, Inc. was... Read More

  • Johnson Matthey

    Johnson Matthey is a British multinational speciality chemicals and sustainable technologies company with major operations in Cambridge and Royston.... Read More

  • specialises in creating ready-to-culture mature human cells for research which are used as models in science, drug discovery and toxicology.... Read More